180 Life Sciences IPO year
What is the IPO year of 180 Life Sciences?
The IPO year of 180 Life Sciences Corp. is 2020
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on NASDAQ compared to 180 Life Sciences
What does 180 Life Sciences do?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Companies with ipo year similar to 180 Life Sciences
- Acusensus Ltd has IPO year of 2019
- Grayscale Ethereum Trust (ETH) has IPO year of 2019
- Powerwrap Ltd has IPO year of 2019
- Powerwrap has IPO year of 2019
- National Rural Utilities Cooper has IPO year of 2019
- Listed Funds Trust has IPO year of 2019
- 180 Life Sciences has IPO year of 2020
- Globally Local Technologies has IPO year of 2021
- uniQure N.V has IPO year of 2021
- Trustpilot plc has IPO year of 2021
- IQVIA has IPO year of 2021
- ACTIA S.A has IPO year of 2021
- Remark has IPO year of 2021